参考文献/References:
[1].国家心血管病中心. 中国心血管健康与疾病报告2023[M]. 北京:中国协和医科大学出版社,2024.
[2].范华霞,罗芳,代静,等. 老年冠心病患者肌少症发生情况与心功能的相关性研究[J]. 中华老年心脑血管病杂志,2023,25(8):814-817.
[3].Li H,Ma F,Li Y,et al. Occurrence of sarcopenia in elderly patients with coronary heart disease and its association with short-term prognosis[J].BMC Cardiovasc Disord,2025,25(1):28.
[4].Nakakubo S,Doi T,Tsutsumimoto K,et al. Sleep duration and progression to sarcopenia in Japanese community-dwelling older adults:a 4 year longitudinal study[J]. J Cachexia Sarcopenia Muscle,2021,12(4):1034-1041.
[5].Cruz-Jentoft AJ,Bahat G,Bauer J,et al. Sarcopenia:revised European consensus on definition and diagnosis[J]. Age Ageing,2019,48(1):16-31.
[6].Souza HCD,Philbois SV,Veiga AC,et al. Heart rate variability and cardiovascular fitness:what we know so far[J].Vasc Health Risk Manag,2021,17:701-711.
[7].Liu S,Zhang L,Li S.Advances in nutritional supplementation for sarcopenia management[J]. Front Nutr,2023,10:1189522.
[8].Glenn A J,Wang F,Tessier A J,et al. Dietary plant-to-animal protein ratio and risk of cardiovascular disease in 3 prospective cohorts[J]. Am J Clin Nutr,2024,120(6):1373-1386.
[9].Xiong A,Li H,Lin M,et al. Effects of active vitamin D analogues on muscle strength and falls in elderly people:an updated meta-analysis[J]. Front Endocrinol (Lausanne),2024,15:1327623.
[10].Zhang Z,Qiu S,Wang Z,et al. Vitamin D levels and five cardiovascular diseases:a Mendelian randomization study[J]. Heliyon,2023,10(1):e23674.
[11].Hung M,Birmingham WC,Ocampo M,et al. The role of vitamin D in cardiovascular diseases[J]. Nutrients,2023,15(16):3547.
[12].Hu B,Chen J,Shi YHL. Association between serum 25(OH)D and risk of all-cause mortality in adults with prior cardiovascular disease:a cohort study from NHANES 2007-2018[J]. BMC Cardiovasc Disord,2023,23(1):240.
[13].Zhou Y,Jiang M,Sun JY, et al. The association between vitamin d levels and the 10-year risk of atherosclerotic cardiovascular disease:a population-based study[J]. J Cardiovasc Nurs,2023,38(5):E178-E186.
[14].Lin X,Chen X,Liu S,et al. Associations of serum 25(OH)D with risk of recurrent cardiovascular events in individuals with coronary heart disease[J]. J Clin Endocrinol Metab,2023,108(12):e1712-e1719.
[15].H?m?l?inen O,Tirkkonen A,Savikangas T,et al. Low physical activity is a risk factor for sarcopenia:a cross-sectional analysis of two exercise trials on community-dwelling older adults[J]. BMC Geriatr,2024,24(1):212.
[16].Anagnostis P, Gkekas NK, Achilla C,et al. Type 2 diabetes mellitus is associated with increased risk of sarcopenia: a systematic review and meta-analysis[J]. Calcif Tissue Int,2020,107(5):453-463.
[17].Yang DR,Wang MY,Zhang CL,et al. Endothelial dysfunction in vascular complications of diabetes:a comprehensive review of mechanisms and implications[J]. Front Endocrinol (Lausanne),2024,15:1359255.
[18].He N,Zhang Y,Zhang L,et al. Relationship between sarcopenia and cardiovascular diseases in the elderly:an overview[J]. Front Cardiovasc Med,2021,8:743710.
[19].Nichols S,O’Doherty AF,Taylor C,et al. Low skeletal muscle mass is associated with low aerobic capacity and increased mortality risk in patients with coronary heart disease-a CARE CR study[J]. Clin Physiol Funct Imaging,2019,39(1):93-102.
[20].Xue Q,Wu J,Ren Y,et al. Sarcopenia predicts adverse outcomes in an elderly population with coronary artery disease:a systematic review and meta-analysis[J]. BMC Geriatr,2021,21(1):493.
[21].Zhang N,Zhu WL,Liu XH,et al. Prevalence and prognostic implications of sarcopenia in older patients with coronary heart disease[J]. J Geriatr Cardiol,2019,16(10):756-763.
[22].Jimenez-Gutierrez GE,Martínez-Gómez LE,Martínez-Armenta C,et al. Molecular mechanisms of inflammation in sarcopenia:diagnosis and therapeutic update[J]. Cells,2022,11(15):2359.
[23].Wu J,Lin S,Chen W,et al. TNF-α contributes to sarcopenia through caspase-8/caspase-3/GSDME-mediated pyroptosis[J]. Cell Death Discov,2023,9(1):76.
[24].Tian X,Lou S,Shi R. From mitochondria to sarcopenia:role of 17β-estradiol and testosterone[J]. Front Endocrinol (Lausanne),2023,14:1156583.
[25].Evans K,Abdelhafiz D,Abdelhafiz AH. Sarcopenic obesity as a determinant of cardiovascular disease risk in older people:a systematic review[J]. Postgrad Med,2021,133(8):831-842.
[26].Afsar B,Afsar RE,Caliskan Y,et al. Renin angiotensin system-induced muscle wasting:putative mechanisms and implications for clinicians[J]. Mol Cell Biochem,2025,480(4):1935-1949.
[27].Trinity JD, Drummond MJ, Fermoyle CC,et al. Cardiovasomobility:an integrative understanding of how disuse impacts cardiovascular and skeletal muscle health[J]. J Appl Physiol (1985),2022,132(3):835-861.
[28].Taylor BA, Thompson PD. Statin-associated muscle disease:advances in diagnosis and management[J]. Neurotherapeutics,2018,15(4):1006-1017.
[29].Kuzuya M. Drug-related sarcopenia as a secondary sarcopenia[J]. Geriatr Gerontol Int,2024,24(2):195-203.
[30].Wei S, Nguyen TT, Zhang Y,et al.Sarcopenic obesity:epidemiology,pathophysiology, cardiovascular disease,mortality,and management[J]. Front Endocrinol (Lausanne),2023,14:1185221.
[31].Aditya JB,Nitin K,Saptarshi B,et al. Sarcopenic obesity as a risk factor for cardiovascular disease: an underrecognized clinical entity[J]. Heart Int,2023,17(2):6-11.
[32].Bernardes P,Marinheiro R,Sousa A R,et al. Sarcopenic obesity-a hidden problem in cardiovascular risk[J]. Metabolites,2025,15(2):85.
[33].Bi B,Dong X,Yan M,et al. Dyslipidemia is associated with sarcopenia of the elderly:a meta-analysis[J]. BMC Geriatr,2024,24(1):181.
[34].中华医学会老年医学分会, 国家老年疾病临床医学研究中心(湘雅医院). 中国肌肉减少症诊疗指南（2024版）[J]. 中华医学杂志,2025,105(3):181-203.
[35].Li M,Liang Y,Wu B,et al. Sex-specific prognostic utility of the sarcopenia index in all-cause mortality risk for patients with heart failure[J]. Front Nutr,2025,12:1472596.
[36].中国医疗保健国际交流促进会临床营养健康学分会,中国抗癌协会肿瘤营养专业委员会,李增宁.老年肌肉减少症患者筛查诊断与营养干预指南[J].肿瘤代谢与营养电子杂志,2024,11(1):45-55.
[37].中华医学会心血管病学分会,中华心血管病杂志编辑委员会.中国慢性冠脉综合征患者诊断及管理指南[J].中华心血管病杂志,2024,52(06):589-614.
[38].刘海霞,周萍,张一娜.肌少症的诊断与治疗[J].中华骨质疏松和骨矿盐疾病杂志,2021,14(4):434-440.
[39].Jeeyavudeen MS, Pappachan JM, Arunagirinathan G. Statin-related muscle toxicity:an evidence-based review[J]. touchREV Endocrinol,2022,18(2):89-95.
[40].Lin MH,Chiu SY,Chang PH,et al. Hyperlipidemia and statins use for the risk of new diagnosed sarcopenia in patients with chronic kidney:a population-based study[J].Int J Environ Res Public Health,2020,17(5):1494.
相似文献/References:
[1]赵丹 周鹏.达比加群及其逆转剂在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):801.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.034]
ZHAO DanZHOU Peng.Dabigatran and Reversal in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(12):801.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.034]
[2]陈元 楚天舒 武力勇.瘦素抵抗、瘦素受体基因多态性与冠状动脉粥样硬化性心脏病的相关性进展[J].心血管病学进展,2019,(8):1130.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.015]
CHEN Yuan,CHU Tianshu,WU Liyong.Leptin Resistance,Leptin Receptor Gene Polymorphism and Coronary Atherosclerotic Heart Disease[J].Advances in Cardiovascular Diseases,2019,(12):1130.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.015]
[3]石文坚 花蕾 孟祥光 袁义强.环状RNA在冠状动脉粥样硬化性心脏病中的研究进展[J].心血管病学进展,2019,(9):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
SHI Wenjian,HUA Lei,MENG Xiangguang,et al.CircRNA in Coronary Atherosclerotic Heart Disease[J].Advances in Cardiovascular Diseases,2019,(12):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
[4]孙涛 左权 周辉 刘安康 梁诚 汤圣兴.末梢桡动脉和无鞘技术在冠状动脉介入治疗中的应用现状[J].心血管病学进展,2020,(5):456.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.005]
[5]奚云萍 臧雁翔 李为民.临床SYNTAX计分及其衍生计分在冠心病血运重建预后中的应用价值[J].心血管病学进展,2020,(5):452.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.004]
XI Yunping,ZANG Yanxiang,LI Weimin.Value of Clinical SYNTAX Score and Its Derivative Score in Prognosis of Coronary Artery Disease with Revascularization[J].Advances in Cardiovascular Diseases,2020,(12):452.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.004]
[6]肖亚楠 高传玉 朱中玉.低剂量替格瑞洛在冠心病中的应用前景[J].心血管病学进展,2020,(7):706.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.009]
XIAO Yanan,GAO Chuanyu,ZHU Zhongyu.Application Prospects of Low-dose Ticagrelor in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2020,(12):706.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.009]
[7]史云聪,王立立 郭艺芳.维生素D与心血管疾病相关性研究进展[J].心血管病学进展,2020,(8):826.[doi:10.16806/j.cnki.issn.1004-3934.20.08.011]
SHI YuncongWANG LiliGUO Yifang.Vitamin D And Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(12):826.[doi:10.16806/j.cnki.issn.1004-3934.20.08.011]
[8]李英 刘兴鹏.常见心血管病服药依从性[J].心血管病学进展,2020,(10):1016.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.000]
LI Ying,LIU Xingpeng.Medication Adherence For Common Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2020,(12):1016.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.000]
[9]肖亚楠 高传玉.经皮冠脉介入术后短程双联抗血小板治疗的研究进展[J].心血管病学进展,2021,(4):318.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.008]
XIAO Yanan,GAO Chuanyu.Short-term Dual Antiplatelet Therapy after Percutaneous Coronary Intervention[J].Advances in Cardiovascular Diseases,2021,(12):318.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.008]
[10]吉蓉 寿锡凌.秋水仙碱在冠状动脉粥样硬化性心脏病防治中的研究进展与争议[J].心血管病学进展,2022,(1):60.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.016]
JI Rong,SHOU Xiling.Research Progress and Controversy of Colchicine in Prevention and Treatment of Coronary Atherosclerotic Heart Disease[J].Advances in Cardiovascular Diseases,2022,(12):60.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.016]